����ӰԺ

����ӰԺ today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal’s pipeline.

����ӰԺ today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.

Krishnan will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence enabling growth.

Vice President of Business Transformation Matt Blume, will host a panel session at the upcoming Bio Supply Management Alliance Conference, to be held at the Crowne Plaza Suites Hotel, Foster City, California, on March 8 – 9, 2023.

The report highlights ����ӰԺ’s progress against its previously published targets and commitments in the areas of environmental, social, and governance (ESG).

����ӰԺ today announced that its Global Director of Clinical Supply Management, Stephanie Graham, is to speak at the upcoming Clinical Outsourcing Group Conference, to be held in London, U.K., on Feb. 21-22, 2023.

The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.

The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT.

Joseph A. Ferraro joins ����ӰԺ as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in February 2023 and is responsible for managing ����ӰԺ’s global legal and compliance operations.